Multi-center and Multi-modal Deep Learning Study of Gastric Cancer
NCT ID: NCT05001321
Last Updated: 2021-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
3300 participants
OBSERVATIONAL
2021-07-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
NCT06451393
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250
Recurrence and Prognosis Prediction Model for Gastric Cancer
NCT07243847
DLCS for Predicting Neoadjuvant Chemotherapy Response
NCT05617469
Interpretable Machine Learning Models for Prognosis in Gastric Cancer Patients
NCT06548464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training Group
Based on the inclusion criteria, 2000 gastric cancer patients will be recruited in the analysis. And a model will be constructed based on deep learning.
The whole abdomen contrast-enhanced CT scan
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
H&E stained sections and slides
HE pathological examination was performed on all specimens of enrolled patients.
Internal Validation Group
Based on the inclusion criteria, 1000 gastric cancer patients will be recruited in this group to verify the sensitivity and specificity of the constructed model.
The whole abdomen contrast-enhanced CT scan
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
H&E stained sections and slides
HE pathological examination was performed on all specimens of enrolled patients.
External Validation Group
Based on the inclusion criteria, 300 gastric cancer patients from 5 other medical centers will be recruited in this group to verify the sensitivity and specificity of the constructed model.
The whole abdomen contrast-enhanced CT scan
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
H&E stained sections and slides
HE pathological examination was performed on all specimens of enrolled patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The whole abdomen contrast-enhanced CT scan
All the participants were measured by the whole abdomen contrast-enhanced CT scan.
H&E stained sections and slides
HE pathological examination was performed on all specimens of enrolled patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Preoperative enhanced abdominal CT;
* Available detailed clinical and pathological data;
* Integrated follow-up data.
Exclusion Criteria
* Overall survival was less than 3 months;
* No detailed information could be collected.
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Second Hospital of Shandong University
OTHER
Chaoyang Central Hospital
OTHER
The General Hospital of Fushun Mining Bureau
UNKNOWN
The fourth People's Hospital of Changzhou
UNKNOWN
First Hospital of Jinzhou Medical University
UNKNOWN
First Hospital of China Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kai Li
Deputy Director of surgical Oncology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai Li, MD
Role: PRINCIPAL_INVESTIGATOR
First Hospital of China Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The fourth People's Hospital of Changzhou
Changzhou, Jiangsu, China
Chaoyang Central Hospital
Chaoyang, Liaoning, China
The General Hospital of Fushun Mining Bureau
Fushun, Liaoning, China
First Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
The Second Hospital of Shandong University
Ji'nan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FirstHCMU_DL_oncology
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.